SCHEMBL3755149

SCHEMBL3755149

CC(C)Sc1nc2sc(-c3ccccc3)cc2c(=O)n1NC(=O)CC12CC3CC(CC(C3)C1)C2

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GLA P06280 1/20 0.54
▸ KDM4E B2RXH2 6/20 0.43
▸ HPGD P15428 3/20 0.43
▸ CYP1A2 P05177 1/20 0.43
▸ CYP2C9 P11712 1/20 0.43
▸ CYP2C19 P33261 1/20 0.43
▸ ALDH1A1 P00352 8/20 0.43
▸ MAPT P10636 4/20 0.43
▸ NPC1 O15118 4/20 0.43
▸ RAB9A P51151 3/20 0.43
▸ KMT2A Q03164 3/20 0.43
▸ SMN1; SMN2 Q16637 2/20 0.43
▸ PTP4A3 O75365 1/20 0.42
▸ NPSR1 Q6W5P4 1/20 0.41
▸ P2RX7 Q99572 3/20 0.41
▸ PTGS2 P35354 1/20 0.40
▸ TP53 P04637 3/20 0.40
▸ POLB P06746 2/20 0.40
▸ HTT P42858 1/20 0.40
▸ LMNA P02545 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3755679 0.77 KMT2A (0.49) GLAKDM4EHPGDCYP1A2CYP2C19
SCHEMBL3765565 0.72 P2RX7 (0.48) GLAKDM4EALDH1A1KMT2ASMN1; SMN2
SCHEMBL3755792 0.72 KMT2A (0.44) GLACYP2C9CYP2C19ALDH1A1KMT2A
SCHEMBL3760650 0.71 GLA (1.00) GLAKDM4EHPGDCYP1A2CYP2C9
SCHEMBL3760532 0.71 ALDH1A1 (0.57) ALDH1A1MAPTRAB9AKMT2AP2RX7
SCHEMBL3761284 0.70 HTT (0.58) CYP1A2CYP2C9CYP2C19ALDH1A1KMT2A
SCHEMBL3749463 0.69 TGM2 (0.47) GLAKDM4ECYP2C9CYP2C19ALDH1A1
SCHEMBL3762001 0.68 KMT2A (0.50) GLAKDM4EALDH1A1KMT2ASMN1; SMN2
SCHEMBL3785819 0.68 P2RX7 (0.44) KDM4EALDH1A1KMT2ASMN1; SMN2P2RX7
SCHEMBL3759965 0.68 P2RX7 (0.45) GLACYP2C19ALDH1A1KMT2ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2010138828-A2 POTASSIUM CHANNEL MODULATORS ABBOTT LABORATORIES (US) 2010-12-02 — — WO claimed
US-20100305109-A1 POTASSIUM CHANNEL MODULATORS ABBOTT LABORATORIES (US) 2010-12-02 — — US claimed
US-8962639-B2 Potassium channel modulators ABBVIE INC. (US) 2015-02-24 — — US disclosed
WO-2010138828-A2 POTASSIUM CHANNEL MODULATORS ABBOTT LABORATORIES (US) 2010-12-02 — — WO disclosed
US-20100305109-A1 POTASSIUM CHANNEL MODULATORS ABBOTT LABORATORIES (US) 2010-12-02 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100305109-A1 POTASSIUM CHANNEL MODULATORS KCNQ1, KCNQ2, KCNJ2 GLA 3444/4885KDM4E 680/4885HPGD 1570/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback